Acrux Limited (ACR) is a specialty pharmaceutical company with a track record of developing, registering and commercialising a portfolio of topically applied generic pharmaceutical products with a primary focus on the US market.
Find out what a historical investment in Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt would be worth today using our ACRO stock calculator.
Buying ACRO shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in ACRO
What is the ticker symbol of Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt?
The ticker symbol for Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt is ACRO.
How much is one share of ACRO?
One share of ACRO is valued at $0.00 as of 20 November 2026.
What is the market capitalisation of Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt ACRO?
As of 20 November 2026 Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt has a market cap of $6.12M.
What is the P/E ratio of ACRO?
The Price to Earnings ratio of ACRO is -0.71.
What is the Earnings Per Share of ACRO?
The Earnings Per Share of ACRO is -$0.00.
What is the 52-week high for Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt stock?
The Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt 52-week high stock price is $0.00.
What is the 52-week low for Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt stock?
The Acrux Call 0.0525 AUD Acrux 19Feb2027 Opt 52-week low stock price is $0.00.
Can I buy ACRO shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy ACRO shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.